000149853 001__ 149853
000149853 005__ 20250128160610.0
000149853 0247_ $$2doi$$a10.1016/j.ejogrb.2020.09.031
000149853 0248_ $$2sideral$$a120488
000149853 037__ $$aART-2020-120488
000149853 041__ $$aeng
000149853 100__ $$0(orcid)0000-0002-2801-416X$$aPérez-López, F.R.
000149853 245__ $$aAssociation of female genital mutilation and female sexual dysfunction: A systematic review and meta-analysis
000149853 260__ $$c2020
000149853 5203_ $$aObjective: To meta-analyze possible associations between female genital mutilation (FGM) and female sexual dysfunction, dyspareunia and pelvic pain. Method: A systematic literature search was performed in PubMed, EMBASE, Scopus, Web of Science, African Index Medicus and Cochrane Library. The PICO protocol included Population: Studies evaluating girls or women; Intervention/Exposure: participants with FGM; Comparison: participants without FGM; Outcomes: female sexual function, dyspareunia or pelvic pain using validated tests. Random effect models were used for meta-analyses, and standardized mean differences (SMDs) and their 95 % confidence intervals (CIs) for any of the measured continuous outcomes were calculated when possible. Risk of bias was assessed with the Newcastle-Ottawa Scale. Results: Fifteen studies (n = 6672 participants) reported on the outcomes of the 19-item Female Sexual Function Index (FSFI). The meta-analysis of the total FSFI score showed a SMD of -1.43 (95 % CI -2.17, -0.69) suggestive of female sexual dysfunction. In addition, scores for the six FSFI domains were significantly lower in women with FGM: SMDs for desire -0.62 (95 % CI -1.01, -0.22), arousal -0.88 (95 % CI -1.41, -0.35), lubrication -0.95 (95 % CI -1.45, -0.46), orgasm -1.07 (95 % CI -1.63, -0.50), satisfaction -0.96 (95 % CI -1.52, -0.41) and pain -0.48 (95 % CI -0.91, -0.05). Estimation of the prevalence of female sexual dysfunction with the FSFI was not possible since different cut-offs values were used in those studies that reported for this outcome. No other searched outcomes using other tools were reported. Conclusion: FGM seriously alters female sexual function as assessed with the FSFI, globally and per domain.
000149853 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000149853 590__ $$a2.435$$b2020
000149853 591__ $$aREPRODUCTIVE BIOLOGY$$b22 / 30 = 0.733$$c2020$$dQ3$$eT3
000149853 591__ $$aOBSTETRICS & GYNECOLOGY$$b49 / 83 = 0.59$$c2020$$dQ3$$eT2
000149853 592__ $$a0.841$$b2020
000149853 593__ $$aReproductive Medicine$$c2020$$dQ2
000149853 593__ $$aObstetrics and Gynecology$$c2020$$dQ2
000149853 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000149853 700__ $$0(orcid)0000-0001-9056-2143$$aOrnat, L.$$uUniversidad de Zaragoza
000149853 700__ $$aLópez-Baena, M.T.
000149853 700__ $$aPérez-Roncero, G.R.$$uUniversidad de Zaragoza
000149853 700__ $$0(orcid)0000-0003-4720-8231$$aTajada-Duaso, M.C.$$uUniversidad de Zaragoza
000149853 700__ $$aChedrau, P.
000149853 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000149853 7102_ $$11013$$2645$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Obstetricia y Ginecología
000149853 773__ $$g254 (2020), 236-244$$pEur. j. obstet., gynecol., reprod. biol.$$tEuropean Journal of Obstetrics and Gynecology and Reproductive Biology$$x0301-2115
000149853 8564_ $$s2810348$$uhttps://zaguan.unizar.es/record/149853/files/texto_completo.pdf$$yVersión publicada
000149853 8564_ $$s2732697$$uhttps://zaguan.unizar.es/record/149853/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000149853 909CO $$ooai:zaguan.unizar.es:149853$$particulos$$pdriver
000149853 951__ $$a2025-01-28-14:57:18
000149853 980__ $$aARTICLE